Therapeutic anti-melanoma compounds

• US 20020169132A1
• Filed: 03/19/2001
• Published: 11/14/2002
• Est. Priority Date: 03/20/2000
• Status: Abandoned Application

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Nicolette, Charles A.
• Application Number:
  US09/812,238
• Publication Number:
  US 20020169132A1
• Time in Patent Office: Days
• US Class Current: 514/16
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing and immune response and administering immunotherapy to a subject by delivering the compositions of the invention.

Claims

1. A compound having the structure:

1;

SFDQVPFSV

26. An antibody that specifically recognizes and binds a compound of any of claims 1 to 8.

27. A method for inducing an immune response in a subject, comprising delivering an effective amount of a compound of any of claims 1 to 8 to the subject.

32. An immune effector cell that has been raised in vitro or in vivo in the presence and at the expense of an antigen presenting cell that presents the compound of any of claims 1 to 8 in the context of an MHC molecule.

33. A method of adoptive immunotherapy, comprising administering an effective amount of the immune effector cell of claim 32.

2. A compound having the structure:

3. A compound having the structure:

4. A compound having the structure:

5. A compound having the structure:

6. A compound having the structure:

7. A compound having the structure:

8. A compound having the structure:

8;

HVDQVPFSV

9. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are S and F respectively.

10. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are F and S respectively.

25. A polynucleotide that encodes a peptide of any of claims 9 to 16.

11. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are G and V respectively.

12. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are M and T respectively.

13. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are A and I respectively.

14. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are L and I respectively.

15. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are M and V respectively.

16. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are H and V respectively.

17. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

3.

18. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

5.

19. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

7.

20. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

9.

21. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

11.

22. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

13.

28. The method of claim 27, wherein the compound is delivered in the context of an MHC molecule.

29. The method of claim 28, wherein the MHC molecule presents the compound on the surface of an antigen presenting cell.

30. The method of claim 27, wherein the compound is delivered as a polynucleotide that encodes the compound.

31. A method of immunotherapy, comprising administering to a subject an effective amount of an antibody of claim 26.

23. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

15.

24. A polynucleotide that encodes an amino acid sequence comprising the amino acid of SEQ ID NO:

17.